CH672230A5
(es)
|
1987-10-15 |
1989-11-15 |
Nestle Sa |
|
FR2634104B1
(fr)
*
|
1988-07-18 |
1991-10-18 |
Union Coop Agricole |
Hydrolysat partiel de proteines de lactoserum, procede enzymatique de preparation de cet hydrolysat, et aliment lacte dietetique hypoallergenique le contenant
|
DE4002204A1
(de)
*
|
1990-01-26 |
1991-08-01 |
Westfalen Milchwerke |
Diaetetisches nahrungsmittel fuer patienten mit niereninsuffizienz
|
NL9001692A
(nl)
*
|
1990-04-26 |
1991-11-18 |
Cooeperatieve Melkproductenbed |
Werkwijze voor de bereiding van een olie-in-water emulsie.
|
JP3065116B2
(ja)
*
|
1991-02-25 |
2000-07-12 |
株式会社第一化成 |
透明な乳清タンパク質加工品の製造法
|
JP3059595B2
(ja)
*
|
1992-11-20 |
2000-07-04 |
森永乳業株式会社 |
沈澱を生じない乳清蛋白質分解物の製造法
|
US5350590A
(en)
*
|
1992-12-15 |
1994-09-27 |
Beatreme Foods Inc. |
Protein fat replacer and method of manufacture thereof
|
US6051256A
(en)
|
1994-03-07 |
2000-04-18 |
Inhale Therapeutic Systems |
Dispersible macromolecule compositions and methods for their preparation and use
|
US6290991B1
(en)
|
1994-12-02 |
2001-09-18 |
Quandrant Holdings Cambridge Limited |
Solid dose delivery vehicle and methods of making same
|
US5965532A
(en)
*
|
1996-06-28 |
1999-10-12 |
Trustees Of Tufts College |
Multivalent compounds for crosslinking receptors and uses thereof
|
US20030203036A1
(en)
*
|
2000-03-17 |
2003-10-30 |
Gordon Marc S. |
Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
|
EP2305235A1
(en)
|
1997-04-02 |
2011-04-06 |
The Brigham And Women's Hospital, Inc. |
Means of ascertaining an individual's risk profile for atherosclerotic disease
|
CA2333931C
(en)
|
1998-07-15 |
2013-09-03 |
Brigham And Women's Hospital, Inc. |
Polysaccharide vaccine for staphylococcal infections
|
US6106874A
(en)
*
|
1998-11-18 |
2000-08-22 |
Abbott Laboratories |
Calcium fortified juice-based nutritional supplement and process of making
|
EP1255455A2
(en)
|
2000-02-17 |
2002-11-13 |
Welch Foods, Inc. |
Calcium-fortified, grape-based products and methods for making them
|
AU4351201A
(en)
|
2000-03-08 |
2001-09-17 |
Massachusetts Inst Technology |
Heparinase iii and uses thereof
|
EP1328261A2
(en)
*
|
2000-04-12 |
2003-07-23 |
Minerva Biotechnologies Corporation |
Treatment of neurodegenerative disease
|
US7575761B2
(en)
*
|
2000-06-30 |
2009-08-18 |
Novartis Pharma Ag |
Spray drying process control of drying kinetics
|
AU2001277230A1
(en)
*
|
2000-08-01 |
2002-02-13 |
Inhale Therapeutic Systems, Inc. |
Apparatus and process to produce particles having a narrow size distribution andparticles made thereby
|
RU2174756C1
(ru)
*
|
2000-09-18 |
2001-10-20 |
Борисов Александр Борисович |
Пищевой продукт
|
DE10062056A1
(de)
*
|
2000-12-15 |
2002-07-04 |
Henkel Ecolab Gmbh & Co Ohg |
Verfahren zur Reinigung von Ionenaustauscher-Kunststoffharzen
|
US8524279B2
(en)
|
2001-11-01 |
2013-09-03 |
Novartis Ag |
Spray drying methods and related compositions
|
DE60221621T2
(de)
*
|
2001-11-26 |
2008-05-21 |
Nestec S.A. |
Lagerstabiles Nahrungsmittelprodukt enthaltend Molkenprotein, Verfahren zu seiner Herstellung und Verwendung
|
US20030165574A1
(en)
*
|
2002-03-01 |
2003-09-04 |
Ward Loren Spencer |
Compositions and methods for treatment of body weight conditions
|
EP1518120A4
(en)
|
2002-03-11 |
2008-08-13 |
Momenta Pharmaceuticals Inc |
ANALYSIS OF SULFATE POLYSACCHARIDES
|
EP1483283A4
(en)
|
2002-03-13 |
2007-04-11 |
Signum Biosciences Inc |
MODULATION OF PROTEIN METHYLATION AND PHOSPHOPROTEIN PHOSPHATE
|
JP3833129B2
(ja)
*
|
2002-03-19 |
2006-10-11 |
株式会社Adeka |
濃縮牛乳状組成物
|
GB0216562D0
(en)
*
|
2002-04-25 |
2002-08-28 |
Bradford Particle Design Ltd |
Particulate materials
|
US9339459B2
(en)
|
2003-04-24 |
2016-05-17 |
Nektar Therapeutics |
Particulate materials
|
CA2508870C
(en)
|
2002-12-30 |
2012-10-16 |
Nektar Therapeutics |
Prefilming atomizer
|
US7399496B2
(en)
*
|
2003-02-07 |
2008-07-15 |
Glanbia Nutritionals (Ireland) Limited |
Hydrolyzed whey protein compositions
|
PL1897548T3
(pl)
|
2003-02-28 |
2014-03-31 |
Univ Johns Hopkins |
Regulacja komórek T
|
WO2005019819A1
(en)
|
2003-08-20 |
2005-03-03 |
Biosite, Inc. |
Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
|
CA2534816A1
(en)
|
2003-06-12 |
2004-12-23 |
Evan Newell |
Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
|
US7355593B2
(en)
*
|
2004-01-02 |
2008-04-08 |
Smart Technologies, Inc. |
Pointer tracking across multiple overlapping coordinate input sub-regions defining a generally contiguous input region
|
US20050163887A1
(en)
*
|
2004-01-23 |
2005-07-28 |
Land O' Lakes, Inc. |
Method of producing heat stable whey protein and products made therefrom
|
NZ550944A
(en)
*
|
2004-04-02 |
2009-12-24 |
Univ Tennessee Res Foundation |
Dairy components effective for fat loss
|
AU2005274937B2
(en)
|
2004-07-15 |
2011-08-18 |
Medivir Ab |
IAP binding compounds
|
CA2577442A1
(en)
|
2004-08-17 |
2006-03-02 |
The Johns Hopkins University |
Pde5 inhibitor compositions and methods for treating cardiac indications
|
EP1797183B1
(en)
*
|
2004-09-02 |
2012-08-01 |
Yale University |
Regulation of oncogenes by micrornas
|
WO2006034454A1
(en)
*
|
2004-09-23 |
2006-03-30 |
The Trustees Of The University Of Princeton |
Bcl-2 family member and bh-3 only proteins for use in development of peptidomimetics
|
EP1809759B1
(en)
|
2004-10-06 |
2013-09-11 |
The Brigham And Women's Hospital, Inc. |
Relevance of achieved levels of markers of systemic inflammation following treatment
|
NZ537456A
(en)
*
|
2004-12-24 |
2007-10-26 |
Fonterra Co Operative Group |
Whey products and a process for preparing a modified whey protein concentrate
|
US7923041B2
(en)
|
2005-02-03 |
2011-04-12 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
WO2006084033A1
(en)
*
|
2005-02-03 |
2006-08-10 |
Signum Biosciences, Inc. |
Compositions and methods for enhancing cognitive function
|
US8841259B2
(en)
*
|
2005-02-24 |
2014-09-23 |
Joslin Diabetes Center |
Compositions and methods for treating vascular permeability
|
EA012810B1
(ru)
|
2005-02-25 |
2009-12-30 |
Тетралоджик Фармасеутикалс |
Димерные ингибиторы ингибиторов белков апоптоза (iap)
|
WO2006110731A2
(en)
*
|
2005-04-11 |
2006-10-19 |
University Of Tennessee Research Foundation |
Stable dairy components effective for fat loss
|
US8354384B2
(en)
*
|
2005-06-23 |
2013-01-15 |
Yale University |
Anti-aging micrornas
|
WO2007011905A2
(en)
|
2005-07-19 |
2007-01-25 |
The University Of Tennessee Research Foundation |
Lpa2 receptor agonist inhibitors of cftr
|
NZ565953A
(en)
|
2005-07-27 |
2012-01-12 |
Univ Florida |
Small compounds that correct protein misfolding and uses thereof
|
US20100256046A1
(en)
*
|
2009-04-03 |
2010-10-07 |
Tetralogic Pharmaceuticals Corporation |
Treatment of proliferative disorders
|
JP2009509128A
(ja)
*
|
2005-08-09 |
2009-03-05 |
テトラロジック ファーマシューティカルズ コーポレーション |
増殖性疾患の治療
|
US20080021198A1
(en)
*
|
2005-10-12 |
2008-01-24 |
Yigong Shi |
Modulators of protein phosphatase 2A and PP2A methyl esterase
|
US8658608B2
(en)
*
|
2005-11-23 |
2014-02-25 |
Yale University |
Modified triple-helix forming oligonucleotides for targeted mutagenesis
|
EP1963364A2
(en)
*
|
2005-12-01 |
2008-09-03 |
University of Pittsburgh - Of the Commonwealth System of Higher Education |
Compounds and methods for inhibiting apoptosis
|
AR064235A1
(es)
*
|
2006-07-24 |
2009-03-25 |
Tetralogic Pharmaceuticals Cor |
Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
|
US20100056495A1
(en)
*
|
2006-07-24 |
2010-03-04 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
WO2008014240A2
(en)
|
2006-07-24 |
2008-01-31 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
CL2007002167A1
(es)
*
|
2006-07-24 |
2009-01-23 |
Tetralogic Pharm Corp |
Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
|
US20100143499A1
(en)
*
|
2006-07-24 |
2010-06-10 |
Tetralogic Pharmaceuticals Corporation |
Dimeric iap inhibitors
|
US20080153773A1
(en)
*
|
2006-08-08 |
2008-06-26 |
Yigong Shi |
Modulators of phosphotyrosyl phosphatase activator
|
US20100092480A1
(en)
*
|
2006-10-13 |
2010-04-15 |
The Trustees Of The University Of Princeton |
Modulators of protein phosphatase 2a
|
US7645616B2
(en)
*
|
2006-10-20 |
2010-01-12 |
The University Of Hong Kong |
Use of lipocalin-2 as a diagnostic marker and therapeutic target
|
JP2010515434A
(ja)
|
2007-01-05 |
2010-05-13 |
マサチューセッツ インスティテュート オブ テクノロジー |
Flavobacteriumheparinum由来のスルファターゼを使用する組成物および方法
|
JP2010515464A
(ja)
*
|
2007-01-11 |
2010-05-13 |
イエール・ユニバーシテイ |
Hiv細胞表面受容体の標的化不活性化のための組成物および方法
|
WO2008109773A2
(en)
*
|
2007-03-06 |
2008-09-12 |
Cornell Research Foundation, Inc. |
Chronic obstructive pulmonary disease susceptibility and related compositions and methods
|
WO2008116216A1
(en)
*
|
2007-03-22 |
2008-09-25 |
Medical College Of Georgia Research Institute, Inc. |
Compositions and methods for inhibiting cancer metastasis
|
WO2008122039A2
(en)
*
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
US9139876B1
(en)
|
2007-05-03 |
2015-09-22 |
Momenta Pharmacueticals, Inc. |
Method of analyzing a preparation of a low molecular weight heparin
|
CN101711287B
(zh)
|
2007-06-08 |
2016-04-27 |
由卫生与公众服务部代表的美利坚合众国政府 |
确定肝细胞癌亚型和检测肝癌干细胞的方法
|
JP2009000091A
(ja)
*
|
2007-06-25 |
2009-01-08 |
Sanei Gen Ffi Inc |
抱気性乳清タンパク質の調製方法及び該方法によって調製される食品
|
US20090274682A1
(en)
*
|
2008-02-05 |
2009-11-05 |
The Trustees Of Princeton University |
Demethylation and inactivation of protein phosphatase 2a
|
WO2009108745A1
(en)
*
|
2008-02-26 |
2009-09-03 |
The Trustees Of Princeton University |
Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
|
JP2011515078A
(ja)
*
|
2008-03-01 |
2011-05-19 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
SPARC特異的miRNAを使用する、治療、診断、及び拮抗物質発見方法
|
JP2011519951A
(ja)
*
|
2008-05-07 |
2011-07-14 |
アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー |
miRNAによる薬物治療の増強
|
US9273136B2
(en)
*
|
2008-08-04 |
2016-03-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Fully human anti-human NKG2D monoclonal antibodies
|
EP2328412A4
(en)
|
2008-09-17 |
2012-03-14 |
Tetralogic Pharm Corp |
IPA INHIBITORS
|
EP2331103A1
(en)
*
|
2008-09-22 |
2011-06-15 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Nuclear factor kappa b pathway inhibitor composition and use of same
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
US8309356B2
(en)
*
|
2009-04-01 |
2012-11-13 |
Yale University |
Pseudocomplementary oligonucleotides for targeted gene therapy
|
WO2010124188A1
(en)
|
2009-04-23 |
2010-10-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human ror1 antibodies
|
ES2675236T3
(es)
|
2009-04-30 |
2018-07-09 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Schweinfurthinas y usos de las mismas
|
US8877199B2
(en)
|
2009-05-15 |
2014-11-04 |
The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
B cell surface reactive antibodies
|
IN2012DN00352A
(es)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
US8283372B2
(en)
|
2009-07-02 |
2012-10-09 |
Tetralogic Pharmaceuticals Corp. |
2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
|
WO2011011797A2
(en)
|
2009-07-24 |
2011-01-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Cytokine compositions and methods of use thereof
|
EP2287304A1
(en)
|
2009-08-17 |
2011-02-23 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
|
AU2010301042B2
(en)
|
2009-10-01 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
|
CN102791742B
(zh)
*
|
2010-01-19 |
2014-12-24 |
动量制药公司 |
评价肝素制剂
|
WO2011133802A1
(en)
|
2010-04-21 |
2011-10-27 |
Helix Therapeutics, Inc. |
Compositions and methods for treatment of lysosomal storage disorders
|
WO2011133803A1
(en)
|
2010-04-21 |
2011-10-27 |
Helix Therapeutics, Inc. |
Compositions and methods for targeted inactivation of hiv cell surface receptors
|
EP2595613B1
(en)
|
2010-07-22 |
2019-01-09 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Compounds for use in a method of preventing or treating viral infection
|
AU2011336650B2
(en)
|
2010-12-01 |
2016-12-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric rabbit/human ROR1 antibodies
|
CA2826043A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-124
|
WO2012106591A1
(en)
|
2011-02-03 |
2012-08-09 |
Mirna Therapeutics, Inc. |
Synthetic mimics of mir-34
|
WO2012115952A1
(en)
|
2011-02-21 |
2012-08-30 |
Momenta Pharmaceuticals, Inc. |
Evaluating heparin preparations
|
WO2012125623A2
(en)
|
2011-03-14 |
2012-09-20 |
Ludwig Institute For Cancer Research Ltd. |
Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
|
US9266960B2
(en)
|
2011-04-08 |
2016-02-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
|
AU2012245198B2
(en)
|
2011-04-21 |
2017-07-13 |
Trustees Of Tufts College |
Compositions and methods for stabilization of active agents
|
EA032666B1
(ru)
|
2011-06-14 |
2019-06-28 |
Бикам Фармасьютикалз, Инк. |
Опсинсвязывающие лиганды и способы их применения
|
SG10201608671SA
(en)
|
2011-07-18 |
2016-12-29 |
Harvard College |
Engineered Microbe-Targeting Molecules and Uses Thereof
|
EP2739734A1
(en)
|
2011-08-03 |
2014-06-11 |
The Charlotte-Mecklenburg Hospital Authority d/b/a Carolina Healthcare System |
Treatment of fibrosis using microrna-19b
|
WO2013058809A1
(en)
|
2011-10-19 |
2013-04-25 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
CN109485730A
(zh)
|
2011-10-20 |
2019-03-19 |
美国卫生和人力服务部 |
抗cd22嵌合抗原受体
|
AU2012346214B2
(en)
|
2011-11-30 |
2017-09-14 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2785178B1
(en)
|
2011-12-01 |
2019-05-01 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
CA3209571A1
(en)
|
2012-03-23 |
2013-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
CA2871490C
(en)
|
2012-04-27 |
2022-10-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
|
US9790278B2
(en)
|
2012-05-07 |
2017-10-17 |
The Trustees Of Dartmouth College |
Anti-B7-H6 antibody, fusion proteins, and methods of using the same
|
CA2876255C
(en)
*
|
2012-06-15 |
2017-01-24 |
Morinaga Milk Industry Co., Ltd. |
Method for manufacturing modified whey composition, modified whey composition, and method for manufacturing calcium-enriched modified whey composition
|
AU2013305888A1
(en)
|
2012-08-21 |
2015-02-26 |
Genesys Research Institute |
Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
|
ES2718903T3
(es)
|
2012-10-24 |
2019-07-05 |
Us Health |
Receptores de antígenos quiméricos M971
|
EP2730170B1
(de)
|
2012-11-13 |
2016-02-10 |
DMK Deutsches Milchkontor GmbH |
Allergenfreie Nahrungsmittelzusammensetzungen
|
EP2931272A1
(en)
|
2012-12-12 |
2015-10-21 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System |
Methods of treating hepatic fibrosis and associated diseases by regulating rev-erb activity
|
WO2014093726A1
(en)
|
2012-12-12 |
2014-06-19 |
The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System |
Methods of treating portal hypertension
|
EP2971166B1
(en)
|
2013-03-14 |
2021-05-19 |
Children's Medical Center Corporation |
Psap peptide for treating cd36 expressing cancers
|
US11376329B2
(en)
|
2013-03-15 |
2022-07-05 |
Trustees Of Tufts College |
Low molecular weight silk compositions and stabilizing silk compositions
|
JP6457482B2
(ja)
|
2013-03-15 |
2019-01-23 |
トラスティーズ オブ タフツ カレッジ |
低分子量絹組成物および絹組成物の安定化
|
WO2014160627A1
(en)
|
2013-03-25 |
2014-10-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 polypeptides, proteins, and chimeric antigen receptors
|
EP2981280A2
(en)
|
2013-04-04 |
2016-02-10 |
IEO - Istituto Europeo di Oncologia Srl |
Thymic stromal lymphopoietin fragments and uses thereof
|
EP2994758B1
(en)
|
2013-05-08 |
2017-12-20 |
Opthea Limited |
Biomarkers for age-related macular degeneration (amd)
|
CN105451726B
(zh)
|
2013-06-25 |
2021-03-16 |
沃尔特和伊利莎豪医学研究所 |
治疗细胞内感染的方法
|
WO2015006543A1
(en)
|
2013-07-10 |
2015-01-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Method for predicting and detecting tumor metastasis in kidney cancer
|
US9925241B2
(en)
|
2013-10-21 |
2018-03-27 |
Salk Institute For Biological Studies |
Mutated fibroblast growth factor (FGF) 1 and methods of use
|
CN105899531B
(zh)
|
2013-12-06 |
2022-02-25 |
美国卫生和人力服务部 |
胸腺基质淋巴细胞生成素受体特异性的嵌合抗原受体及其使用方法
|
CN105828830A
(zh)
|
2013-12-16 |
2016-08-03 |
雀巢产品技术援助有限公司 |
最新鉴定出的用于诱导幼年哺乳动物口服耐受性的肽
|
EP3546474B1
(en)
|
2013-12-18 |
2021-07-07 |
President and Fellows of Harvard College |
Crp capture/detection of gram positive bacteria
|
CN106659764B
(zh)
|
2014-03-26 |
2021-11-02 |
儿童医学中心公司 |
环状鞘脂激活蛋白原肽及其用途
|
ES2966886T3
(es)
|
2014-05-09 |
2024-04-24 |
Univ Yale |
Partículas recubiertas con poliglicerol hiperramificado y métodos de elaboración y uso de las mismas
|
US11918695B2
(en)
|
2014-05-09 |
2024-03-05 |
Yale University |
Topical formulation of hyperbranched polymer-coated particles
|
WO2016044383A1
(en)
|
2014-09-17 |
2016-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd276 antibodies (b7h3)
|
WO2016079527A1
(en)
|
2014-11-19 |
2016-05-26 |
Tetralogic Birinapant Uk Ltd |
Combination therapy
|
WO2016097773A1
(en)
|
2014-12-19 |
2016-06-23 |
Children's Cancer Institute |
Therapeutic iap antagonists for treating proliferative disorders
|
EP3270937A4
(en)
|
2015-03-26 |
2018-09-12 |
The Trustees Of Dartmouth College |
Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
|
US10844392B2
(en)
|
2015-06-05 |
2020-11-24 |
Ibio, Inc. |
Materials and methods for producing endostatin fusion polypeptides in plant cells
|
US10633427B2
(en)
|
2015-06-26 |
2020-04-28 |
Prindex S.R.L. |
Diagnosis and therapy of multiple sclerosis
|
EP3313519B1
(en)
|
2015-06-29 |
2023-05-31 |
Children's Medical Center Corporation |
Jak-stat inhibitors for the treatment of congenital myopathies
|
US10435457B2
(en)
|
2015-08-06 |
2019-10-08 |
President And Fellows Of Harvard College |
Microbe-binding molecules and uses thereof
|
EP3389393A1
(en)
|
2015-12-18 |
2018-10-24 |
Nestec S.A. |
Heat sterilized high protein compositions comprising whey protein and at least one component selected from (i) a saccharide, (ii) a phosphate and (iii) a citrate
|
JP2019509023A
(ja)
|
2016-01-20 |
2019-04-04 |
ザ・スクリップス・リサーチ・インスティテュート |
Ror2抗体組成物及び関連する方法
|
AU2017210327A1
(en)
|
2016-01-20 |
2018-08-09 |
Nbe-Therapeutics Ag |
ROR1 antibody compositions and related methods
|
CA3014795A1
(en)
|
2016-02-16 |
2017-08-24 |
Yale University |
Compositions and methods for treatment of cystic fibrosis
|
WO2017143042A2
(en)
|
2016-02-16 |
2017-08-24 |
Yale University |
Compositions for enhancing targeted gene editing and methods of use thereof
|
JP2019513769A
(ja)
|
2016-04-19 |
2019-05-30 |
ザ ユナイテッド ステイツ オブ アメリカ,アズ レプリゼンテッド バイ ザ セクレタリー,デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
アトピー性皮膚炎を処置するためのグラム陰性種の使用
|
US10293005B2
(en)
|
2016-04-19 |
2019-05-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Use of gram negative species to treat atopic dermatitis
|
US20190391152A1
(en)
|
2016-05-16 |
2019-12-26 |
Checkmab S.R.L. |
Markers selectively deregulated in tumor-infiltrating regulatory t cells
|
WO2017207623A1
(en)
|
2016-05-31 |
2017-12-07 |
Université de Lausanne |
Mirna as biomarkers and regulators of cancer stem cells
|
US20190322643A1
(en)
|
2016-06-29 |
2019-10-24 |
Georgia State University Research Foundation, Inc. |
Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
|
US20190201414A1
(en)
|
2016-07-01 |
2019-07-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
BR112019000731B1
(pt)
*
|
2016-07-15 |
2022-08-30 |
Arla Foods Amba |
Método para preparar uma composição de proteína do soro de leite gelificável por ácido e método para preparar um produto alimentício
|
US20200113821A1
(en)
|
2017-04-04 |
2020-04-16 |
Yale University |
Compositions and methods for in utero delivery
|
CA3099487A1
(en)
|
2017-07-20 |
2019-01-24 |
Nbe-Therapeutics Ag |
Human antibodies binding to ror2
|
WO2019030223A1
(en)
|
2017-08-07 |
2019-02-14 |
Nbe-Therapeutics Ag |
ANTHRACYCLINE ANTIBODY-MEDICINAL CONJUGATES HAVING HIGH IN VIVO TOLERABILITY
|
US11197917B2
(en)
|
2017-12-01 |
2021-12-14 |
ByHeart, Inc. |
Formulations for nutritional support in subjects in need thereof
|
WO2019154884A1
(en)
|
2018-02-07 |
2019-08-15 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Method for determining cancer invasiveness and patient prognosis
|
AU2019243464A1
(en)
*
|
2018-03-30 |
2020-11-05 |
Megmilk Snow Brand Co., Ltd. |
Method for producing composition containing kappa-casein glycomacropeptide
|
JP2021523900A
(ja)
|
2018-05-11 |
2021-09-09 |
フォルテ サブシディアリー,インク. |
皮膚疾病の処置のための組成物
|
CN109045278B
(zh)
*
|
2018-07-09 |
2022-06-21 |
苏州恒瑞健康科技有限公司 |
一种稳定的乳蛋白质液态体系及其应用
|
US11266617B2
(en)
|
2018-10-16 |
2022-03-08 |
Massachusetts Institute Of Technology |
Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
|
JP2022512739A
(ja)
|
2018-10-19 |
2022-02-07 |
ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム |
操作された長鎖散在反復エレメント(line)トランスポゾンおよびそれらの使用方法
|
AU2019409827A1
(en)
|
2018-12-19 |
2021-05-27 |
Société des Produits Nestlé S.A. |
Composition for preventing or reducing transepidermal water loss and improving skin barrier function
|
EP3677693A1
(en)
|
2019-01-03 |
2020-07-08 |
Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO |
Transpochimeric gene trancripts (tcgts) as cancer biomarkers
|
WO2020148677A1
(en)
|
2019-01-18 |
2020-07-23 |
Janssen Biotech, Inc. |
Gprc5d chimeric antigen receptors and cells expressing the same
|
KR20210122275A
(ko)
|
2019-01-30 |
2021-10-08 |
얀센 파마슈티카 엔.브이. |
분자 아형에 기초하여 전립선암을 치료하는 방법
|
WO2020186187A1
(en)
|
2019-03-13 |
2020-09-17 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Methods for treating bladder and urethra dysfunction and disease
|
EP3952886A1
(en)
|
2019-04-10 |
2022-02-16 |
Elevatebio Technologies, Inc |
Flt3-specific chimeric antigen receptors and methods of using the same
|
CA3139032A1
(en)
|
2019-05-22 |
2020-11-26 |
Robert Alexander WESSELHOEFT |
Circular rna compositions and methods
|
WO2020239478A1
(en)
|
2019-05-28 |
2020-12-03 |
Pharma Mar, S.A. |
Trabectedin for treating sarcomas based on genomic markers
|
WO2020257779A1
(en)
|
2019-06-21 |
2020-12-24 |
Yale University |
Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
|
WO2020257776A1
(en)
|
2019-06-21 |
2020-12-24 |
Yale University |
Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
|
KR20220040483A
(ko)
|
2019-07-26 |
2022-03-30 |
얀센 바이오테크 인코포레이티드 |
칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
|
CN114174346A
(zh)
|
2019-07-26 |
2022-03-11 |
詹森生物科技公司 |
抗hk2嵌合抗原受体(car)
|
WO2021022161A1
(en)
|
2019-07-31 |
2021-02-04 |
Yale University |
Compositions and methods for treating sickle cell disease
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
WO2021033089A1
(en)
|
2019-08-16 |
2021-02-25 |
Janssen Biotech, Inc. |
Therapeutic immune cells with improved function and methods for making the same
|
EP4061837A1
(en)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
|
EP4385337A3
(en)
*
|
2019-12-30 |
2024-07-10 |
Arla Foods amba |
Method of producing dense whey protein nanogels, the resulting whey protein nanogels or nanogel compositions, and use of such whey protein nanogels or nanogel compositions
|
IL271778A
(en)
|
2019-12-31 |
2021-06-30 |
Ichilov Tech Ltd |
Methods for treating atopic dermatitis
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
TW202144418A
(zh)
|
2020-03-13 |
2021-12-01 |
美商健生生物科技公司 |
唾液酸結合Ig樣凝集素結合的材料及方法
|
WO2021225781A2
(en)
|
2020-05-07 |
2021-11-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
|
CN116322788A
(zh)
|
2020-05-19 |
2023-06-23 |
奥纳治疗公司 |
环状rna组合物和方法
|
WO2021245285A1
(en)
|
2020-06-05 |
2021-12-09 |
Janssen Pharmaceutica Nv |
Methods of treating prostate cancer based on molecular subtypes
|
CA3195303A1
(en)
|
2020-10-16 |
2022-04-21 |
Gerardus Josephus BOONS |
Glycoconjugates
|
MX2023011273A
(es)
|
2021-03-24 |
2023-12-14 |
Janssen Biotech Inc |
Anticuerpo dirigido a cd22 y cd79b.
|
WO2022237974A1
(en)
|
2021-05-12 |
2022-11-17 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Krab-containing zinc finger protein and cancer
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
EP4352226A1
(en)
|
2021-06-07 |
2024-04-17 |
Yale University |
Peptide nucleic acids for spatiotemporal control of crispr-cas binding
|
WO2022271955A1
(en)
|
2021-06-23 |
2022-12-29 |
Musc Foundation For Research Development |
Novel targeted shrna nanoparticles for cancer therapy
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
IL312490A
(en)
|
2021-11-08 |
2024-07-01 |
Orna Therapeutics Inc |
Fat nanoparticle preparations for the administration of circular polynucleotides
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024129982A2
(en)
|
2022-12-15 |
2024-06-20 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|